Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins

X. Kang, P. F. Robbins, E. B. Fitzgerald, R. F. Wang, S. A. Rosenberg, Yutaka Kawakami

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Several epitopes in the human melanoma antigens recognized by HLA-A2- restricted CTLs have a relatively low MHC-binding affinity and as a result may be expressed at very low densities on the cell surface, indicating that these epitopes may not be efficient immunogens. To express these epitopes at higher densities on the surface of antigen-presenting cells and therefore improve their immunogenicity, a DNA construct in which a cDNA fragment encoding the melanoma epitope MART-127-35 or gp100280-288 was inserted between sequences encoding the leader and the HLA-A* 0201 protein. Cells transfected with these epitope-HLA fusion constructs were recognized by HLA-A2-restricted melanoma-reactive CTLs specific for the MART-1 or gp100 epitope. In addition, tumor-reactive CTLs could be induced from PBMCs of patients with metastatic melanoma by in vitro stimulation with HMY-C1R B- cell lines expressing the MART-1 or gp100 epitope-HLA-A* 0201 fusion protein. These epitope-HLA fusion constructs may be useful for the development of immunotherapies for patients with melanoma.

Original languageEnglish
Pages (from-to)202-205
Number of pages4
JournalCancer Research
Volume57
Issue number2
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Major Histocompatibility Complex
Epitopes
Melanoma
T-Lymphocytes
Proteins
HLA-A2 Antigen
Melanoma-Specific Antigens
Antigen-Presenting Cells
Surface Antigens
Immunotherapy
B-Lymphocytes
Complementary DNA
Cell Count
Cell Line
DNA
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kang, X., Robbins, P. F., Fitzgerald, E. B., Wang, R. F., Rosenberg, S. A., & Kawakami, Y. (1997). Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins. Cancer Research, 57(2), 202-205.

Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins. / Kang, X.; Robbins, P. F.; Fitzgerald, E. B.; Wang, R. F.; Rosenberg, S. A.; Kawakami, Yutaka.

In: Cancer Research, Vol. 57, No. 2, 1997, p. 202-205.

Research output: Contribution to journalArticle

Kang, X, Robbins, PF, Fitzgerald, EB, Wang, RF, Rosenberg, SA & Kawakami, Y 1997, 'Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins', Cancer Research, vol. 57, no. 2, pp. 202-205.
Kang, X. ; Robbins, P. F. ; Fitzgerald, E. B. ; Wang, R. F. ; Rosenberg, S. A. ; Kawakami, Yutaka. / Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins. In: Cancer Research. 1997 ; Vol. 57, No. 2. pp. 202-205.
@article{9e0da56b5d8945a1ba92643c78f91a56,
title = "Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins",
abstract = "Several epitopes in the human melanoma antigens recognized by HLA-A2- restricted CTLs have a relatively low MHC-binding affinity and as a result may be expressed at very low densities on the cell surface, indicating that these epitopes may not be efficient immunogens. To express these epitopes at higher densities on the surface of antigen-presenting cells and therefore improve their immunogenicity, a DNA construct in which a cDNA fragment encoding the melanoma epitope MART-127-35 or gp100280-288 was inserted between sequences encoding the leader and the HLA-A* 0201 protein. Cells transfected with these epitope-HLA fusion constructs were recognized by HLA-A2-restricted melanoma-reactive CTLs specific for the MART-1 or gp100 epitope. In addition, tumor-reactive CTLs could be induced from PBMCs of patients with metastatic melanoma by in vitro stimulation with HMY-C1R B- cell lines expressing the MART-1 or gp100 epitope-HLA-A* 0201 fusion protein. These epitope-HLA fusion constructs may be useful for the development of immunotherapies for patients with melanoma.",
author = "X. Kang and Robbins, {P. F.} and Fitzgerald, {E. B.} and Wang, {R. F.} and Rosenberg, {S. A.} and Yutaka Kawakami",
year = "1997",
language = "English",
volume = "57",
pages = "202--205",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins

AU - Kang, X.

AU - Robbins, P. F.

AU - Fitzgerald, E. B.

AU - Wang, R. F.

AU - Rosenberg, S. A.

AU - Kawakami, Yutaka

PY - 1997

Y1 - 1997

N2 - Several epitopes in the human melanoma antigens recognized by HLA-A2- restricted CTLs have a relatively low MHC-binding affinity and as a result may be expressed at very low densities on the cell surface, indicating that these epitopes may not be efficient immunogens. To express these epitopes at higher densities on the surface of antigen-presenting cells and therefore improve their immunogenicity, a DNA construct in which a cDNA fragment encoding the melanoma epitope MART-127-35 or gp100280-288 was inserted between sequences encoding the leader and the HLA-A* 0201 protein. Cells transfected with these epitope-HLA fusion constructs were recognized by HLA-A2-restricted melanoma-reactive CTLs specific for the MART-1 or gp100 epitope. In addition, tumor-reactive CTLs could be induced from PBMCs of patients with metastatic melanoma by in vitro stimulation with HMY-C1R B- cell lines expressing the MART-1 or gp100 epitope-HLA-A* 0201 fusion protein. These epitope-HLA fusion constructs may be useful for the development of immunotherapies for patients with melanoma.

AB - Several epitopes in the human melanoma antigens recognized by HLA-A2- restricted CTLs have a relatively low MHC-binding affinity and as a result may be expressed at very low densities on the cell surface, indicating that these epitopes may not be efficient immunogens. To express these epitopes at higher densities on the surface of antigen-presenting cells and therefore improve their immunogenicity, a DNA construct in which a cDNA fragment encoding the melanoma epitope MART-127-35 or gp100280-288 was inserted between sequences encoding the leader and the HLA-A* 0201 protein. Cells transfected with these epitope-HLA fusion constructs were recognized by HLA-A2-restricted melanoma-reactive CTLs specific for the MART-1 or gp100 epitope. In addition, tumor-reactive CTLs could be induced from PBMCs of patients with metastatic melanoma by in vitro stimulation with HMY-C1R B- cell lines expressing the MART-1 or gp100 epitope-HLA-A* 0201 fusion protein. These epitope-HLA fusion constructs may be useful for the development of immunotherapies for patients with melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0031014423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031014423&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 202

EP - 205

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -